|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNAP29 |
Gene summary for SNAP29 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNAP29 | Gene ID | 9342 |
| Gene name | synaptosome associated protein 29 | |
| Gene Alias | CEDNIK | |
| Cytomap | 22q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | O95721 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9342 | SNAP29 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.90e-05 | 2.95e-01 | -0.1954 |
| 9342 | SNAP29 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.47e-03 | 6.66e-01 | -0.2602 |
| 9342 | SNAP29 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.81e-02 | 3.22e-01 | -0.059 |
| 9342 | SNAP29 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.08e-03 | 2.19e-01 | 0.0674 |
| 9342 | SNAP29 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.45e-02 | 4.14e-01 | 0.0112 |
| 9342 | SNAP29 | A002-C-116 | Human | Colorectum | FAP | 3.08e-02 | -7.78e-02 | -0.0452 |
| 9342 | SNAP29 | LZE4T | Human | Esophagus | ESCC | 4.66e-10 | 2.35e-01 | 0.0811 |
| 9342 | SNAP29 | LZE5T | Human | Esophagus | ESCC | 1.62e-05 | 3.23e-01 | 0.0514 |
| 9342 | SNAP29 | LZE7T | Human | Esophagus | ESCC | 2.71e-03 | 2.43e-01 | 0.0667 |
| 9342 | SNAP29 | LZE8T | Human | Esophagus | ESCC | 2.17e-10 | 3.51e-01 | 0.067 |
| 9342 | SNAP29 | LZE22T | Human | Esophagus | ESCC | 2.15e-02 | 3.99e-01 | 0.068 |
| 9342 | SNAP29 | LZE24T | Human | Esophagus | ESCC | 4.81e-17 | 5.22e-01 | 0.0596 |
| 9342 | SNAP29 | LZE6T | Human | Esophagus | ESCC | 5.11e-03 | 1.59e-01 | 0.0845 |
| 9342 | SNAP29 | P1T-E | Human | Esophagus | ESCC | 1.37e-03 | 3.23e-01 | 0.0875 |
| 9342 | SNAP29 | P2T-E | Human | Esophagus | ESCC | 1.88e-19 | 3.46e-01 | 0.1177 |
| 9342 | SNAP29 | P4T-E | Human | Esophagus | ESCC | 5.70e-36 | 9.81e-01 | 0.1323 |
| 9342 | SNAP29 | P5T-E | Human | Esophagus | ESCC | 1.26e-43 | 8.39e-01 | 0.1327 |
| 9342 | SNAP29 | P8T-E | Human | Esophagus | ESCC | 1.68e-16 | 3.85e-01 | 0.0889 |
| 9342 | SNAP29 | P9T-E | Human | Esophagus | ESCC | 1.89e-21 | 4.14e-01 | 0.1131 |
| 9342 | SNAP29 | P10T-E | Human | Esophagus | ESCC | 8.94e-40 | 6.22e-01 | 0.116 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:0016236 | Colorectum | AD | macroautophagy | 103/3918 | 291/18723 | 6.76e-09 | 4.15e-07 | 103 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0051650 | Colorectum | AD | establishment of vesicle localization | 57/3918 | 161/18723 | 1.47e-05 | 3.15e-04 | 57 |
| GO:0051648 | Colorectum | AD | vesicle localization | 59/3918 | 177/18723 | 7.83e-05 | 1.25e-03 | 59 |
| GO:0022406 | Colorectum | AD | membrane docking | 31/3918 | 86/18723 | 8.67e-04 | 8.45e-03 | 31 |
| GO:0006903 | Colorectum | AD | vesicle targeting | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0140056 | Colorectum | AD | organelle localization by membrane tethering | 28/3918 | 77/18723 | 1.29e-03 | 1.14e-02 | 28 |
| GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
| GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
| GO:0048284 | Colorectum | AD | organelle fusion | 42/3918 | 141/18723 | 8.04e-03 | 4.73e-02 | 42 |
| GO:00224111 | Colorectum | SER | cellular component disassembly | 114/2897 | 443/18723 | 1.17e-08 | 9.59e-07 | 114 |
| GO:00516561 | Colorectum | SER | establishment of organelle localization | 100/2897 | 390/18723 | 1.11e-07 | 6.79e-06 | 100 |
| GO:00162361 | Colorectum | SER | macroautophagy | 79/2897 | 291/18723 | 1.97e-07 | 1.10e-05 | 79 |
| GO:00329841 | Colorectum | SER | protein-containing complex disassembly | 61/2897 | 224/18723 | 4.17e-06 | 1.60e-04 | 61 |
| GO:00516501 | Colorectum | SER | establishment of vesicle localization | 42/2897 | 161/18723 | 3.38e-04 | 5.35e-03 | 42 |
| GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
| GO:00224061 | Colorectum | SER | membrane docking | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04140 | Colorectum | AD | Autophagy - animal | 49/2092 | 141/8465 | 4.58e-03 | 2.20e-02 | 1.40e-02 | 49 |
| hsa041401 | Colorectum | AD | Autophagy - animal | 49/2092 | 141/8465 | 4.58e-03 | 2.20e-02 | 1.40e-02 | 49 |
| hsa041402 | Colorectum | SER | Autophagy - animal | 39/1580 | 141/8465 | 5.43e-03 | 3.28e-02 | 2.38e-02 | 39 |
| hsa041403 | Colorectum | SER | Autophagy - animal | 39/1580 | 141/8465 | 5.43e-03 | 3.28e-02 | 2.38e-02 | 39 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa041305 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0413012 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa041406 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa04130 | Liver | Cirrhotic | SNARE interactions in vesicular transport | 18/2530 | 33/8465 | 2.64e-03 | 1.10e-02 | 6.76e-03 | 18 |
| hsa0414011 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa041301 | Liver | Cirrhotic | SNARE interactions in vesicular transport | 18/2530 | 33/8465 | 2.64e-03 | 1.10e-02 | 6.76e-03 | 18 |
| hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa041302 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa041303 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa041304 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa0413011 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNAP29 | SNV | Missense_Mutation | novel | c.582C>A | p.His194Gln | p.H194Q | O95721 | protein_coding | tolerated(0.26) | benign(0.02) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| SNAP29 | deletion | Frame_Shift_Del | novel | c.688delC | p.Gln230LysfsTer8 | p.Q230Kfs*8 | O95721 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SNAP29 | SNV | Missense_Mutation | novel | c.8N>T | p.Ala3Val | p.A3V | O95721 | protein_coding | deleterious(0.01) | possibly_damaging(0.709) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNAP29 | SNV | Missense_Mutation | novel | c.276G>T | p.Glu92Asp | p.E92D | O95721 | protein_coding | tolerated(0.2) | benign(0.324) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SNAP29 | SNV | Missense_Mutation | rs757889031 | c.521N>G | p.Asp174Gly | p.D174G | O95721 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SNAP29 | SNV | Missense_Mutation | novel | c.444N>C | p.Glu148Asp | p.E148D | O95721 | protein_coding | tolerated(0.27) | benign(0.026) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SNAP29 | SNV | Missense_Mutation | rs371123997 | c.643N>T | p.Arg215Cys | p.R215C | O95721 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SNAP29 | SNV | Missense_Mutation | c.665G>T | p.Gly222Val | p.G222V | O95721 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNAP29 | SNV | Missense_Mutation | c.407N>A | p.Gly136Asp | p.G136D | O95721 | protein_coding | deleterious(0.04) | possibly_damaging(0.495) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNAP29 | SNV | Missense_Mutation | novel | c.548N>T | p.Ala183Val | p.A183V | O95721 | protein_coding | tolerated(0.06) | benign(0.079) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |